Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE:002370)
China · Delayed Price · Currency is CNY 6.62
0.00 (0.00%)
Apr 29, 2026, 3:04 PM CST
SHE:002370 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 318.16 | 323.14 | 402.22 | 416.92 | 372.86 | 312.77 |
Other Revenue | - | - | 2.96 | 3.72 | 0.58 | 2.37 |
| 318.16 | 323.14 | 405.17 | 420.64 | 373.44 | 315.13 | |
Revenue Growth (YoY) | -10.88% | -20.25% | -3.68% | 12.64% | 18.50% | -38.80% |
Cost of Revenue | 210.23 | 216.14 | 284.42 | 288.54 | 247.23 | 210.24 |
Gross Profit | 107.94 | 107 | 120.75 | 132.1 | 126.22 | 104.89 |
Selling, General & Admin | 102.22 | 105.11 | 110.51 | 137.6 | 129.66 | 209.45 |
Research & Development | 16.64 | 15.47 | 14.64 | 21.79 | 26.14 | 28.62 |
Other Operating Expenses | -3.46 | -1.34 | 6.39 | 6.14 | 5.38 | 5.31 |
Operating Expenses | 115.4 | 119.24 | 132.12 | 165.11 | 162.21 | 236.02 |
Operating Income | -7.46 | -12.24 | -11.37 | -33.01 | -35.99 | -131.13 |
Interest Expense | - | - | -30.59 | -47.46 | -52.31 | -56.87 |
Interest & Investment Income | 150.34 | 150.24 | 65.12 | 16.08 | 11.78 | 15.99 |
Currency Exchange Gain (Loss) | - | - | -0.35 | - | - | - |
Other Non Operating Income (Expenses) | -18.65 | -19.24 | 0.55 | -1.07 | -0.97 | -0.03 |
EBT Excluding Unusual Items | 124.23 | 118.76 | 23.36 | -65.45 | -77.49 | -172.04 |
Gain (Loss) on Sale of Investments | 0.53 | 0.83 | 1.64 | 1.78 | -17.32 | -14.95 |
Gain (Loss) on Sale of Assets | -0.06 | -0.06 | -0.01 | 0.4 | 0.04 | 8.61 |
Asset Writedown | -23.1 | -23.1 | -0.16 | -4.71 | -40.27 | -22.06 |
Legal Settlements | - | - | -4.93 | 51.9 | -8.66 | -21.11 |
Other Unusual Items | - | - | 14.58 | 4.53 | 8.39 | -2.6 |
Pretax Income | 101.6 | 96.43 | 34.49 | -11.56 | -135.32 | -224.16 |
Income Tax Expense | 0.08 | 0.12 | 0.25 | 0.31 | -2.63 | 4.12 |
Earnings From Continuing Operations | 101.52 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income to Company | 101.52 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income | 101.52 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income to Common | 101.52 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income Growth | 244.91% | 181.28% | - | - | - | - |
Shares Outstanding (Basic) | 740 | 741 | 685 | 594 | 531 | 531 |
Shares Outstanding (Diluted) | 740 | 741 | 685 | 594 | 531 | 531 |
Shares Change (YoY) | 3.10% | 8.18% | 15.32% | 11.89% | -0.02% | -2.68% |
EPS (Basic) | 0.14 | 0.13 | 0.05 | -0.02 | -0.25 | -0.43 |
EPS (Diluted) | 0.14 | 0.13 | 0.05 | -0.02 | -0.25 | -0.43 |
EPS Growth | 234.53% | 160.00% | - | - | - | - |
Free Cash Flow | 8.5 | 23.84 | 14.44 | 7.19 | -9.06 | -19.62 |
Free Cash Flow Per Share | 0.01 | 0.03 | 0.02 | 0.01 | -0.02 | -0.04 |
Gross Margin | 33.92% | 33.11% | 29.80% | 31.40% | 33.80% | 33.28% |
Operating Margin | -2.35% | -3.79% | -2.80% | -7.85% | -9.64% | -41.61% |
Profit Margin | 31.91% | 29.80% | 8.45% | -2.82% | -35.53% | -72.44% |
Free Cash Flow Margin | 2.67% | 7.38% | 3.56% | 1.71% | -2.43% | -6.23% |
EBITDA | 23.97 | 19.37 | 20.92 | 5.49 | 4.43 | -88.54 |
EBITDA Margin | 7.53% | 5.99% | 5.16% | 1.31% | 1.19% | -28.10% |
D&A For EBITDA | 31.43 | 31.6 | 32.29 | 38.51 | 40.42 | 42.59 |
EBIT | -7.46 | -12.24 | -11.37 | -33.01 | -35.99 | -131.13 |
EBIT Margin | -2.35% | -3.79% | -2.80% | -7.85% | -9.64% | -41.61% |
Effective Tax Rate | 0.08% | 0.13% | 0.71% | - | - | - |
Revenue as Reported | - | - | 405.17 | 420.64 | 373.44 | 315.13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.